GlassScriptPhysician profile
Behrouz Zand
NPI 1619286465
$10,320.55
in general payments reported to CMS, 2019-2025
29 companies · $1,917 in 2025
The $1,917 reported for 2025 was more than what 78% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,010 · 2023: $2,357 · 2024: $5,037 · 2025: $1,917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,825 · Food and Beverage: $3,224 · Travel and Lodging: $1,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,825.00 |
| Food and Beverage | $3,224.17 |
| Travel and Lodging | $1,261.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $5,078.80 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Karyopharm Therapeutics INC. | $928.70 | 2023 | Xpovio |
| Medtronic, INC. | $558.48 | 2022-2023 | Sonicision |
| Myriad Genetic Laboratories, INC. | $553.20 | 2022-2024 | Precisetumor, Myrisk |
| Tempus Ai, INC | $491.42 | 2024-2025 | Xt Cdx |
| Baxter Healthcare | $468.04 | 2024-2025 | Perclot, Seprafilm, Tisseel |
| Stryker Corporation | $434.55 | 2023 | 1688 |
| Glaxosmithkline, LLC. | $350.60 | 2022-2025 | Zejula, Jemperli |
| Astrazeneca Pharmaceuticals LP | $276.40 | 2022-2025 | Lynparza, Imfinzi |
| Dilon Technologies, INC. | $173.87 | 2025 | Hemoblast Bellows |
| Abbvie INC. | $166.01 | 2023-2025 | Vraylar |
| Davol INC. | $162.15 | 2022 | |
| Janssen Biotech, INC. | $89.03 | 2022-2025 | Akeega, Erleada, Talvey |
| Genmab U.S., INC. | $71.04 | 2025 | Tivdak |
| Mimedx Group, INC. | $63.27 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $58.16 | 2022-2025 | |
| Ethicon US, LLC | $53.12 | 2022-2024 | Vistaseal, Stratafix |
| Daiichi Sankyo INC. | $49.42 | 2022-2025 | Enhertu |
| Incyte Corporation | $44.33 | 2025 | Niktimvo, Jakafi, Monjuvi |
| Meditrina | $43.50 | 2023-2024 | |
| Integra Lifesciences Corporation | $37.70 | 2022-2023 | Integra |
| Aroa Biosurgery Incorporated | $31.70 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.21 | 2025 | |
| Immunogen, INC. | $22.05 | 2024 | Elahere |
| Evofem Biosciences, INC. | $19.80 | 2022 | |
| Pfizer INC. | $19.27 | 2023 | |
| Exact Sciences Corporation | $18.60 | 2023 | Cologuard Collection Kit |
| Coopersurgical, INC. | $18.39 | 2022 | |
| Astellas Pharma US INC | $15.74 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Behrouz Zand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.